Schrödinger Halts CDC7 Inhibitor After Two Patient Deaths
Key Points: 1. Schrödinger discontinued its SGR-2921 CDC7 inhibitor program following two treatment-related deaths in a Phase 1 trial. 2. ...
Tag: leukemia
![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/ChatGPT-Image-May-12-2025-at-10_22_23-AM-350x250.png)
2 Minute Medicine: Pharma Roundup – Landmark lung approval, billion-dollar obesity drug deal, oncology safety halt, and GSK’s China push [August 14 2025]
FDA Approves First-Ever Treatment for Non-Cystic Fibrosis Bronchiectasis Late last week, the U.S. Food and Drug Administration approved Insmed’s Brinsupri ...
Overweight body habitus is associated with higher rates of relapse in children with acute lymphoblastic leukemia
1. Among children with acute lymphoblastic leukemia, overweight or obesity at >2 time points (longer duration) was associated with higher ...
Venetoclax plus azacitidine demonstrating efficacy for high-risk myelodysplastic syndromes
1. In patients with treatment-naive high-risk myelodysplastic syndromes (HR MDS), the use of venetoclax (14 days) plus azacitidine was well ...
#VisualAbstract: Blinatumomab Improves Survival in MRD-Negative Acute Lymphoblastic Leukemia in Adults
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
#VisualAbstract: Chronic Lymphocytic Leukemia (CLL) therapy with Ibrutinib and Venetoclax guided by measurable residual disease improves progression-free survival
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
Characterization of cancer development risk following pediatric radiation exposure from computed tomography
Evidence rating level: 3 (Average) 1. Exposure to a higher cumulative number of pediatric CT scans is associated with a ...
Quizartinib improves overall median survival in patients with acute myeloid leukemia
1. Overall survival in the quizartinib group was 31.9 months compared to 15.1 months in the placebo group. 2. Proportion ...
Venetoclax in addition to ibrutinib effective as a treatment for chronic lymphocytic leukemia
1. High genetic risk participants with chronic lymphocytic leukemia (CLL) taking venetoclax in addition to ibrutinib achieved high rates of ...
Maternity genitourinary tract infections associated with increased offspring leukemia risk in Danish cohort
1. In a Danish cohort, maternal genitourinary tract infection during pregnancy was associated with an increased risk of childhood leukemia ...
